DP

Diadema Partners Portfolio holdings

AUM $161M
This Quarter Est. Return
1 Year Est. Return
–
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$125M
AUM Growth
+$36.4M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
117
New
Increased
Reduced
Closed

Top Buys

1
+$18.9M
2
+$15.9M
3
+$9M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$6.88M
5
ARGX icon
argenx
ARGX
+$6.78M

Top Sells

1
+$9.05M
2
+$8.88M
3
+$6.68M
4
BPMC
Blueprint Medicines
BPMC
+$5.6M
5
AZN icon
AstraZeneca
AZN
+$3.93M

Sector Composition

1 Healthcare 100%
2 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
26
Trevi Therapeutics
TRVI
$1.26B
$1.13M 0.3%
+180,000
RLAY icon
27
Relay Therapeutics
RLAY
$1.12B
$1.12M 0.29%
426,346
-79,432
PCRX icon
28
Pacira BioSciences
PCRX
$1.03B
$967K 0.25%
+38,926
URGN icon
29
UroGen Pharma
URGN
$784M
$843K 0.22%
76,220
+26,220
CLYM
30
Climb Bio
CLYM
$131M
$817K 0.21%
669,803
+295,380
CYTK icon
31
Cytokinetics
CYTK
$6.99B
$804K 0.21%
+20,000
REPL icon
32
Replimune Group
REPL
$351M
$727K 0.19%
74,530
-39,470
RVPH icon
33
Reviva Pharmaceuticals
RVPH
$55.4M
$621K 0.16%
+650,723
ALEC icon
34
Alector
ALEC
$308M
$562K 0.15%
456,546
+217,527
QURE icon
35
uniQure
QURE
$3.57B
$387K 0.1%
+36,500
OLMA icon
36
Olema Pharmaceuticals
OLMA
$642M
$376K 0.1%
+100,000
GOSS icon
37
Gossamer Bio
GOSS
$501M
$297K 0.08%
269,589
+51,602
PRQR icon
38
ProQR Therapeutics
PRQR
$293M
$276K 0.07%
207,694
+49,671
ELDN icon
39
Eledon Pharmaceuticals
ELDN
$206M
$219K 0.06%
64,613
-11,181
MREO
40
Mereo BioPharma
MREO
$326M
$169K 0.04%
+492,215
TERN icon
41
Terns Pharmaceuticals
TERN
$736M
$155K 0.04%
56,098
+5,728
SGMT icon
42
Sagimet Biosciences
SGMT
$239M
$150K 0.04%
+46,019
CADL icon
43
Candel Therapeutics
CADL
$293M
$142K 0.04%
25,045
+5,045
ABBV icon
44
AbbVie
ABBV
$406B
– –
-50,000
ACLX icon
45
Arcellx
ACLX
$4.82B
– –
-10,100
AGIO icon
46
Agios Pharmaceuticals
AGIO
$2.46B
– –
0
ALT icon
47
Altimmune
ALT
$338M
– –
0
ALXO icon
48
ALX Oncology
ALXO
$80.3M
– –
-197,680
AMGN icon
49
Amgen
AMGN
$161B
– –
0
ANAB icon
50
AnaptysBio
ANAB
$969M
– –
0
1
2
3 4 5